Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

29.46 +0.80 (+2.79%)
Official Closing Price Updated: 7:00 PM EDT, Sep 28, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,868,385
Open 28.98
Bid (Size) 29.00 (2)
Ask (Size) 29.50 (3)
Prev. Close 28.66
Today's Range 28.77 - 29.60
52wk Range 28.46 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 Consumer Stocks to Sell Before They Die
These are the top consumer stocks to sell before things get worse. These companies are struggling with issues that will take years to fix. 
Via InvestorPlace
2 High Yielders Decimated By The Russia-Ukraine War: Is Now The Time To Buy?
As the Russia-Ukraine war moves forward, the European economy remains in a fragile state. 
Via Benzinga

Performance

YTD
-32.54%
-32.54%
1 Month
-11.02%
-11.02%
3 Month
-32.69%
-32.69%
6 Month
-32.59%
-32.59%
1 Year
-22.58%
-22.58%

More News

Read More
iPhone 14 Popular In China?, Netflix May Lose Comics, Elon Musk's Starlink Slows, Byron Allen Faces $10B Lawsuit And More Top Financial Media Stories Monday, Sept. 26
Via Benzinga
Burberry Finance Chief Joins GSK As First Woman CFO
Via Benzinga
Unilever CEO Alan Jope To Retire Next Year
Via Benzinga
AnaptysBio Sells Royalty Interest In Cancer Drug For $45M
Via Benzinga
SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK
Via Benzinga
7 Stocks to Buy That Can Soar in Good Times or in Bad
Via InvestorPlace
Spero Therapeutics (NASDAQ: SPRO) Enters into Exclusive Licensing Agreement with GSK (NYSE: GSK) for the Commercialization of Tebipenem HBr
Via Spotlight Growth
Exposures Product Safety
Spero Therapeutics (SPRO) Soars 137% on Exclusive License Agreement
Via InvestorPlace
Top Financial Media Stories Thursday, September 22: Facebook Sued For Bypassing Apple Privacy Rules, Walmart Slows Hiring Plans Ahead Of Holiday Season, China Blames US For Northwestern Polytechnical University Hack And More..
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Spero Therapeutics Stock More Than Doubles On GSK Pact For Its Lead Antibiotic
Via Benzinga
Jim Cramer Says This Stock Is A 'Great Spec And I Usually Don't Say That,' And Analysts Approve
Via Benzinga
3 Biotech Stocks to Buy Now for Extraordinary Gains
Via InvestorPlace
Haleon Clocks Double Digit Growth In Interim Revenue, Profits; Sticks To Annual Guidance
Via Benzinga
Haleon Shares Pop After Rejecting Zantac Indemnification Requests From GSK, Pfizer
Via Benzinga
Recent Stock Purchase September 2022
Via Talk Markets
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
Via Benzinga
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
Via Benzinga
Pfizer's Pentavalent Meningococcal Vaccine Candidate Shows Efficacy In Adolescents
Via Benzinga
September 2022 Stock Considerations
Via Talk Markets
Sanofi-GSK COVID-19 Vaccine May See European Approval Soon: Report
Via Benzinga
White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox
Via Benzinga
Novartis Appoints Merck Executive As Research Head
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.